ArticleAtherosclerosis2008
The apolipoprotein(a) gene: linkage disequilibria at three loci differs in African Americans and Caucasians.
Article in Atherosclerosis, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 16 citations in OpenAlex.
- Lipoprotein(a)-Lowering Drugs: A Mini Review.Journal of clinical medicine research · 2025Review
- Lipoprotein(a): Emerging insights and therapeutics.American journal of preventive cardiology · 2024Article
- Lipoprotein(a): a Case for Universal Screening in Youth.Current atherosclerosis reports · 2023Review
- Investigation of a nonsense mutation located in the complex KIV-2 copy number variation region of apolipoprotein(a) in 10,910 individuals.Genome medicine · 2020Article
- Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies.Clinical research in cardiology supplements · 2017Article
- Review
- Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects.Clinical research in cardiology supplements · 2015Article
- Lipoprotein(a) metabolism: potential sites for therapeutic targets.Metabolism: clinical and experimental · 2013Review
- Lipoprotein(a): a promising marker for residual cardiovascular risk assessment.Disease markers · 2013Review
- Lipoprotein(a): genotype-phenotype relationship and impact on atherogenic risk.Metabolic syndrome and related disorders · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Lipoprotein(a) (Lp(a)) is an independent, genetically regulated cardiovascular risk factor. Lp(a) plasma levels are largely determined by the apolipoprotein(a) (apo(a)) component, and differ across ethnicity. Although a number of polymorphisms in the apo(a) gene have been identified, apo(a) genetic regulation is not fully understood. To study the relation between apo(a) gene variants, we constructed haplotypes and assessed linkage equilibrium in African Americans and Caucasians for three widely studied apo(a) gene polymorphisms (apo(a) size, +93 C/T and pentanucleotide repeat region (PNR)). Apo(a) size allele frequency distributions were different across ethnicity (p<0.01). For African Americans, PNR frequencies were similar across apo(a) sizes, suggesting linkage equilibrium. For Caucasians, the PNR and the PNR-C/T haplotype frequencies differed for large and small apo(a), with the T and PNR 9 alleles associated with large apo(a) size (p<0.0002); also, the PNR 9 allele was more common on a T allele, while PNR 8 was more common on a C allele. On a C allele background, small PNR alleles were more common and the PNR 10 allele less common among African Americans than Caucasians (p<0.001). The ethnic difference in apo(a) size distribution remained controlling for C/T and PNR alleles (p=0.023). In conclusion, allele and haplotype frequencies and the nature of the linkage disequilibrium differed between African Americans and Caucasians at three apo(a) gene polymorphisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.